Study S001841

A Randomized, Open-Label, Multicenter, Active-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Switching From Once-Weekly Dulaglutide to Once-Monthly PG-102(MG12) in Patients With Type 2 Diabetes Mellitus Receiving Stable Dulaglutide Therapy

ClinicalTrials.gov record

Registration

Registration: NCT07677891
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 60
Start: 2026-10
Primary completion: 2027-05
Lead sponsor: ProGen. Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:PG-102(MG12); DRUG:Dulaglutide
Results posted: FALSE

Registered primary outcomes

Change in HbA1c from Baseline at Week 32 [[Time Frame: Baseline to Week 32]]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.